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(wileyonlinelibrary.com) DOI: 10.1002/jlcr.3139Good manufacturing practice production of
the system A amino acid transport tracer [11C]
MeAIB on a commercial synthesis module
Johan Hygum Dam and Kjell Någren*In this report, an automated 11C-N-methyl-α-amino-isobutyric acid production on a Tracerlab FXC Pro module is described.
Bioburden to the sterile ﬁlter was minimized during solid-phase extraction formulation of the HPLC puriﬁed product by the
use of sterile aqueous solutions. The optimized solid-phase extraction formulation conditions are fast, give a high recovery of
the product, and effectively remove organic solvents and adjust the pH. The ﬁnal product was obtained within 30–35min,
delivering 1.5–5GBq in 10mL sterile phosphate buffer. The product fulﬁlls in every respect our stringent batch release
speciﬁcations including residual solvents, bioburden, and sterility. The robustness of the automated 11C-N-methyl-α-amino-
isobutyric acid production has been demonstrated during more than 40 productions for preclinical use without any failures
in regard to product amounts or release speciﬁcations.
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The clinical value of positron emission tomography (PET) using
labeled amino acids for oncologic applications is well
established.1 The ﬁrst successful tracer for this purpose was
[11C]methionine, which has found wide applications in brain
tumor imaging2 and many other oncologic applications.1 A
number of 18F-labeled amino acid analogs such as [18F]FET, [18F]
6-F-DOPA, and [18F]FACBC have also shown their clinical values.3
Carbon-11 labeled tracers have several advantages for clinical
PET such as a lower radiation dose to the patient and the
possibility to perform several PET studies per day using different
tracers. Although widely used, [11C]methionine imaging is
complicated by uptake in non-tumor processes such as
inﬂammation and the fast metabolism of the tracer. Ideally, a
tracer should have high speciﬁcity for a physiologic process such
as an amino acid uptake system and a low rate of metabolism to
preclude arterial blood sampling. 11C-N-methyl-α-amino-
isobutyric acid ([11C]MeAIB) is a tracer that is very selective for
the system A amino acid transport and is metabolically
stable in vivo4 and thus fulﬁll these two criteria. This tracer has
a low radiation burden to the patient5 and can be used to study
system A amino acid transport both in healthy organs such as
muscles6 and in various tumors such as head and neck cancer,7
chest cancer,8 glioblastoma multiforma,9 and prostate cancer.10
The published production of [11C]MeAIB was performed on a
home-built remote-controlled synthesis system that included
evaporation of the HPLC solvent from the puriﬁed product using
a rotary evaporator.4 From a good manufacturing practice (GMP)
perspective, these production conditions are today regarded as
suboptimal and not suitable for radiopharmaceuticals for clinical
use. Most commercial carbon-11 synthesis devices are equipped
with storage vessels and valves intended to be used forJ. Label Compd. Radiopharm 2013solid-phase extraction (SPE) formulation purposes. This greatly
simpliﬁes the cleaning procedures when compared to a rotary
evaporator. The purpose of this work was to establish conditions
for automated GMP production of [11C]MeAIB using a
commercial synthesis module including solid-phase extraction
for the formulation of the puriﬁed product in order to fulﬁll
stringent batch release speciﬁcations including residual organic
solvents and bioburden of the product.
Experimental
General
Production of [11C]methyl triﬂate ([11C]MeOTf) on the GE Tracerlab FXC Pro
was performed with manufacturer’s speciﬁed chemicals. The labeling
precursor, α-amino-isobutyric acid methyl ester hydrochloride, was prepared
according to Någren et al.4 and was crystallized from 100% sterile ethanol.
Phosphoric acid (0.2 and 1.0M), disodium hydrogen phosphate (Na2HPO4,
2%), and hydrochloric acid (0.1M) were autoclaved in a Systec DX-23
according to European Pharmacopoeia (Ph. Eur.) before use. Sodium
hydroxide (NaOH, 2.0M)was prepared fromPh. Eur. standardmaterials. MeOH
for HPLC, ≥99.9 %; acetonitrile for HPLC, ≥99.9 %; potassium dihydrogen
phosphate, KH2PO4, anhydrous, for HPLC; pentamethylpiperidine, >97%;
and reference MeAIB, ≥98 % were obtained from Sigma-Aldrich. Strata-X-C
12mL gigatubes (33μm, 1g sorbent) were obtained from Phenomenex.
These SPE columns were preconditioned with 10mL ethanol (96%) and
20mL phosphoric acid (1M) before use. Pall Acrodisc HT Tuffryn 0.2μm
sterile ﬁlters were obtained from VWR International, Denmark.Copyright © 2013 John Wiley & Sons, Ltd.
Figure 1. Synthesis of [
11
C]MeAIB.
igure 2. Semi-preparative HPLC chromatogram from the puriﬁcation of [
11
C]MeAIB. Upper: UV detection at 200 nm, lower: radiodetector. (1) [
11
C]MeAIB and (2)
nidentiﬁed by-product.
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uFigure 3. Analytical HPLC chromatograms of the ﬁnal product with co-injected referenceM
www.jlcr.org Copyright © 2013 JohThe semi-preparative HPLC system consisted of a SYKAM S1021 HPLC
pump, a six-way Valco Instruments Co. Inc. injector (C6W) with a 2mL
loop, a Phenomenex Luna NH2 250× 10mm, 5μm HPLC column, a
Knauer K-2001 UV detector, and a Geiger-Müller tube radioactivity
detector. The analytical Hitachi LaChrome Elite HPLC system consisted
of an L-2130 HPLC pump, an L-2200 autosampler, an L-2455 diode array
detector, and a Bioscan FC-4000 with FC-4100 dual Bismuth Germanium
Oxide radiodetector. A Varian 3900 gas chromatograph equipped with a
Varian VF-200ms, 30m×0.32mm inner diameter capillary column and a
ﬂame ionization detector was used to quantify residual solvents.eAIB. Upper: UV detection at 210nm, lower: radiodetector. (1) [
11
C]MeAIB and (1′): MeAIB.
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2013
J. H. Dam and K. NågrenEndotoxin levels were measured with an Endosafe®-portable test system
from Charles River. Bioburden and sterility tests were performed by
Statens Serum Institut, Copenhagen, Denmark. The pH was measured
with a SevenMulti system from Mettler Toledo. Radioactivity was
measured using a Capintec CRC®-15 PET dose calibrator.Labeling procedure
The labeling procedure is shown in Figure 1. [11C]MeOTf was prepared on
a Tracerlab FXC Pro module (GE Healthcare) by standard in-line gas-phase
conversions from [11C]CO2 and was trapped in the reaction mixture
cooled to 5°C. This mixture consisted of 1mg precursor in 300μL 1:1
CH3CN:CH3OH and 2μL pentamethylpiperidine. After delivery of [
11C]
MeOTf, the vial was heated to 60° for 1min, at which point, 0.1mL NaOH
(2M) was added. The heating was continued for 3min, and the reaction
mixture was diluted with 0.3mL HPLC eluent.Preparative HPLC
Following dilution, the reaction mixture was automatically injected onto
the semi-preparative HPLC column through the 2mL loop. The mobile
phase consisted of 3:1 acetonitrile:7.5 mM KH2PO4, pH 4.3, and the
puriﬁcation was performed at a ﬂow of 9.5mL/min and monitored by
UV detection at 200 nm and by radiodetection. The puriﬁed [11C]MeAIB
fraction was collected using manual computer control by comparison
with a master chromatogram.Formulation
The HPLC puriﬁed [11C]MeAIB was subjected to solvent exchange by SPE.
The solution was diluted with 20mL sterile phosphoric acid (0.2M) and
passed through a Strata-X-C column. Following loading of [11C]MeAIB
on the SPE column, it was washed with 15mL sterile hydrochloric acid
(0.1 M) and 3mL isotonic sterile saline. The [11C]MeAIB was then eluted
from the column with sterile 10mL Na2HPO4 (2%) through a 0.2μm
sterile ﬁlter into a sterile product vial.Table 1. Quality control of [11C]MeAIB productions
Item Methodology
Radioactivity Dose calibrator
Appearance Visual inspection
Radiochemical
purity
HPLC
pH pH meter
Half-life Dose calibrator
γ-ray spectra γ-spectrometer
Ethanol Gas chromatograph
Acetonitrile Gas chromatograph
Sterile ﬁlter
integrity
Bubble point
Endotoxins LAL
Sterility Culture media (Ph. Eur.)
Bioburden* Culture media (Ph. Eur.)
Shelf life HPLC and visual inspection at 30–60min
Tests of sterility, bioburden, and shelf life were performed for thr
determined for six productions.
*The productions for test of bioburden were performed without
Copyright © 2013 JohJ. Label Compd. Radiopharm 2013Analytical methods
Radiochemical purity was analyzed by HPLC on a Phenomenex Bondclone
NH2 (300× 3.9mm, 10μm) HPLC column, at a ﬂow of 2mL/min and at a
UV detection at 210 nm. The elution was performed as a gradient as
follows: A, 7.5mM KH2PO4 (pH 4.3) and B, CH3CN:H2O (500:70); 95 to
50% B, 0–8min. Identiﬁcation was performed by co-injection with
reference MeAIB.
The amount of residual solvents was determined by gas
chromatography using an injector temperature of 220°C, a detector
temperature of 270°C, and a column temperature of 40°C for 5min,
followed by a 50°C/min increase up to 240°C. Helium gas ﬂow was
2mL/min. The concentrations of CH3CN and ethanol in the product
solution were measured by comparison with a reference solution
containing 350 ppm CH3CN and 1% (w/v) ethanol.Results and discussion
Generally, 10–15GBq of [11C]MeOTf was produced on the Tracerlab
FXC Pro module. We conﬁrmed the reported high synthesis yield of
[11C]MeAIB from [11C]MeOTf, which was in the order of 70% decay
corrected radiochemical yield. Total synthesis time from end of
bombardment to the crude product was 20–21min.
The Phenomenex Luna NH2 column proved to be a proper
substitute for the Phenomenex Selectosil SAX column, which is
no longer commercially available. This robust column has to be
thoroughly washed before ﬁrst use and then withstands the basic
injected solution well. [11C]MeAIB fraction eluted at 5.5–6.0min
and a minor radiochemical impurity, which eluted at 4.5min, was
well separated from the main product (Figure 2). This impurity
increased with decreasing speciﬁc radioactivity.
More than 99.7% of [11C]MeAIB was retained by the Strata-X-C
column. A wash with 15 mL 0.1M HCl followed by a wash with 3
mL saline resulted in a neutral pH of the product, and an
acceptable acetonitrile content. Using the optimized SPE
procedure, more than 99% of the applied [11C]MeAIB was
recovered in the eluted product fraction within 4–7min.Acceptance criteria Results
1500–5000MBq
Clear and colorless Clear and colorless
≥95% ≥99.4%
4.5–8.5 6.5–6.7
19.9–20.9min 20.1–20.6min
511 ± 25 KeV 511–520 KeV
≤0.7% 0.1–0.5%
≤350 ppm 135–347 ppm
≥3.1 bar ≥3.1 bar
≤17.5 EU/mL <1.0 EU/mL
No growth No growth
<1 colony forming unit/4mL <1 colony forming unit/4.5mL
≥95% and clear and colorless 100% and clear and colorless
ee productions, and the other quality control parameters were
sterile ﬁltration of the product solutions.
www.jlcr.orgn Wiley & Sons, Ltd.
J. H. Dam and K. NågrenThe optimized procedure for production of [11C]MeAIB gives up
to 5GBq of a clear and colorless solution within 30–35min from
end of bombardment. The speciﬁc radioactivity, determined for
other 11C-radiopharmaceuticals produced on our Tracerlab FXC Pro
module, has been in the order of 20–70GBq/μmol. Radiochemical
purity of the ﬁnal product, determined by HPLC, has been higher
than 99% (Figure 3), and the radiochemical purity was maintained
for 60min in batches up to 5GBq. The result of our validation of
the [11C]MeAIB production is shown in Table 1.
Conclusions
The automated [11C]MeAIB production has shown to be very
reliable. The optimized conditions for SPE formulation of the HPLC
puriﬁed product are fast, give a high recovery of the product, and
effectively remove organic solvents and adjust the pH. More than
40 productions have been performed for in vivo imaging of human
glioblastoma in nude rats.11 There have been no failures in these
productions. The production and quality control conditions that
comply with cGMP requirements have been validated and
accepted by the Danish Health and Medicines Authority. The
product fulﬁlls in every respect our stringent batch release
speciﬁcations including residual solvents, bioburden, and sterility.www.jlcr.org Copyright © 2013 JohConﬂict of Interest
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